Digital Commons Network^™

Early Antibody Treatment, Inflammation, And Risk Of Post-Covid Conditions, Kelly A. Gebo, Sonya L. Heath, Yuriko Fukuta, Xianming Zhu, Sheriza Baksh, Allison G. Abraham, Feben Habtehyimer, David Shade, Jessica Ruff, Malathi Ram, Oliver Laeyendecker, Reinaldo E. Fernandez, Eshan U. Patel, Owen R. Baker, Shmuel Shoham, Edward R. Cachay, Judith S. Currier, Jonathan M. Gerber, Barry Meisenberg, Donald N. Forthal, Laura L. Hammitt, Moises A. Huaman, Adam Levine, Giselle S. Mosnaim, Bela Patel, James H. Paxton, Jay S. Raval, Catherine G. Sutcliffe, Shweta Anjan, Thomas Gniadek, Seble Kassaye, Janis E. Blair, Karen Lane, Nichol A. Mcbee, Amy L. Gawad, Piyali Das, Sabra L. Klein, Andrew Pekosz, Evan M. Bloch, Daniel Hanley, Arturo Casadevall, Aaron A R Tobian, David J. Sullivan

Pathology Research and Scholarship

Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical …

The Standard Of Care Is Standard For A Reason: Commentary On "Optimal Dosing Of Heparin For Prophylactic Anticoagulation In Critically Ill Covid-19 Patients: A Systematic Review And Meta-Analysis Of Randomized Clinical Trials", Victoria Milano, Jacob Hurt, Nathan D. Nielsen

Pathology Research and Scholarship

No abstract provided.

Transfusion Reactions Associated With Covid-19 Convalescent Plasma In Outpatient Clinical Trials, Moises A. Huaman, Jay S. Raval, James H. Paxton, Giselle S. Mosnaim, Bela Patel, Shweta Anjan, Barry R. Meisenberg, Adam C. Levine, Christi E. Marshall, Anusha Yarava, Aarthi G. Shenoy, Sonya L. Heath, Judith S. Currier, Yuriko Fukuta, Janis E. Blair, Emily S. Spivak, Joann R. Petrini, Patrick B Broderick, William Rausch, Marieelena Cordisco, Jean Hammel, Benjamin Greenblatt, Valerie C Cluzet, Daniel Cruser, Kevin Oei, Matthew Abinante, Laura L. Hammitt, Catherine G. Sutcliffe, Donald N. Forthal, Martin S Zand, Edward R. Cachay, Seble G. Kassaye, Malathi Ram, Ying Wang, Piyali Das, Karen Lane, Nichol A Mcbee, Amy L Gawad, Nicky Karlen, Daniel E Ford, Oliver Laeyendecker, Andrew Pekosz, Sabra L. Klein, Stephan Ehrhardt, Bryan Lau, Sheriza N. Baksh, David M. Shade, Arturo Casadevall, Daniel F. Hanley, Jiangda Ou, Thomas J. Gniadek, Alyssa Ziman, Shmuel Shoham, Kelly A. Gebo, Evan M. Bloch, Aaron A R Tobian, David J. Sullivan, Jonathan M. Gerber

Pathology Research and Scholarship

BACKGROUND: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials.

STUDY DESIGN AND METHODS: We analyzed data pertaining to transfusion-related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.

RESULTS: The combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 …

Preliminary Incidence And Trends Of Infections Caused By Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2022, Miranda J. Delahoy, Hazel J. Shah, Daniel Lowell Weller, Logan C. Ray, Kirk Smith, Suzanne Mcguire, Rosalie T. Trevejo, Elaine Scallan Walter, Katie Wymore, Tamara Rissman, Marcy Mcmillian, Sarah Lathrop, Bethany Laclair, Michelle M. Boyle, Stic Harris, Joanna Zablotsky-Kufel, Kennedy Houck, Carey J. Devine, Carey E. Lau, Robert V. Tauxe, Beau B. Bruce, Patricia M. Griffin, Daniel C. Payne

Pathology Research and Scholarship

Each year, infections from major foodborne pathogens are responsible for an estimated 9.4 million illnesses, 56,000 hospitalizations, and 1,350 deaths in the United States (1). To evaluate progress toward prevention of enteric infections in the United States, the Foodborne Diseases Active Surveillance Network (FoodNet) conducts surveillance for laboratory-diagnosed infections caused by eight pathogens transmitted commonly through food at 10 U.S. sites. During 2020-2021, FoodNet detected decreases in many infections that were due to behavioral modifications, public health interventions, and changes in health care-seeking and testing practices during the COVID-19 pandemic. This report presents preliminary estimates of pathogen-specific annual incidences during …

Symptom Duration And Resolution With Early Outpatient Treatment Of Convalescent Plasma For Coronavirus Disease 2019: A Randomized Trial, Sheriza N. Baksh, Sonya L. Heath, Yuriko Fukuta, David Shade, Barry Meisenberg, Evan M. Bloch, Aaron A R Tobian, Emily S. Spivak, Bela Patel, Jonathan Gerber, Jay S. Raval, Donald Forthal, James Paxton, Giselle Mosnaim, Shweta Anjan, Janis Blair, Edward Cachay, Judith Currier, Piyali Das, Moises Huaman, Catherine Sutcliffe, Anusha Yarava, Arturo Casadevall, David Sullivan, Daniel Hanley, Kelly A Gebo

Pathology Research and Scholarship

BACKGROUND: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP reduces time to symptom resolution among outpatients.

METHODS: We evaluated symptom resolution at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. We also assessed the prevalence of symptom clusters at day 14 between treatments. Clusters were defined based on biologic clustering, impact on ability to work, and an algorithm.

RESULTS: Among 1070 outpatients followed up after transfusion, 381 of 538 (70.8%) receiving CCP and 381 of 532 (71.6%) receiving …